Catabasis Pharmaceuticals, Inc.

Most Recent Annual Report

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

2019 Annual Report and Form 10K

Catabasis Pharmaceuticals, Inc. has reached its limit for free report views.

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

Archived Annual Reports

- 2018 Annual Report
- PDF
- 2017 Annual Report
- PDF
- 2016 Annual Report
- PDF
Show 1 more archive
- 2015 Annual Report
- PDF

About Catabasis Pharmaceuticals, Inc.

11-50 Employees

Based in Boston, Massachusetts

Visit website

At Catabasis Pharmaceuticals, their mission is to bring hope and life-changing therapies to patients and their families. Their lead program is edasalonexent, an NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy.

Ticker:: CATB
Exchange:: NASDAQ (See More NASDAQ Companies)
Industry:: Biotechnology (See More Biotechnology Companies)
Sector:: Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?